Guggenheim last night initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target The company has a promising interleukin-2-inducible T-cell kinase franchise strategy and “several credible upside catalysts” residing out t in the next 18-24 months, the analyst tells investors in a research note. The firm sees three “pipeline-in-a-product” opportunities for Aclaris.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics initiated with a Buy at Guggenheim
- Aclaris Therapeutics price target raised to $10 from $8 at Wedbush
- Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial
- Aclaris Reports Positive ATI-052 Phase 1a Trial Results
- Aclaris Therapeutics management to meet virtually with Craig-Hallum